Baxter International Inc. BAX

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Baxter International (BAX) has drawn fresh attention after publishing its 2026 Connected Hospital Report, spotlighting how U.S. hospitals are using technology maturity benchmarks to pursue operational efficiency, workflow automation, and data integration priorities. Baxter International’s recent Connected Hospital Report lands after a mixed run in the stock, with the share price up 20.41% year to date and 8.25% over 90 days but down 10.14% over the past month. Total shareholder return sits at...

DEERFIELD, Ill., September 30, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the release of its 2026 Connected Hospital Report, offering new insights into how hospitals across the United States are leveraging technology investments to drive clinical and operational outcomes.

Growth is driven by rising cardiovascular disease, telehealth adoption, and advances in wearable ECG devices, implantable monitors, AI analytics, and cloud platforms. North America leads, while Asia-Pacific is expected to grow fastest.Dublin, Sept. 28, 2026 (GLOBE NEWSWIRE) -- "Remote Cardiac Monitoring Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Remote Cardiac Monitoring Mark

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Baxter International has underperformed the Nasdaq over the past year, and analysts are cautious about the stock’s prospects.

A year of stagnation is setting up an important test

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 22.1% over the past six months while the S&P 500 was up 12.1%.

Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.

In recent days, IonQ appointed two new board members, veteran finance executive Dr. Eric Ball and former SkyWater chairman and Samsung North America CEO Timothy Baxter, adding deep capital markets and semiconductor leadership experience to its governance. The combination of Ball’s large-scale financing and M&A track record with Baxter’s chip industry and go-to-market expertise could be important as IonQ integrates SkyWater and scales its merchant quantum supply ambitions. Next, we’ll...

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.

John Rogers is expected to take the Deerfield, Illinois-based medical device company’s CFO seat on Oct. 1.

John Rogers, who has experience leading change at companies, is expected to help Baxter’s turnaround gain traction. He joins Baxter after the company sold two business units.

DEERFIELD, Ill., August 19, 2026--Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed John Rogers as executive vice president and chief financial officer (CFO), reporting to Baxter president and chief executive officer (CEO), Andrew Hider, effective Oct. 1, 2026.